OGN logo

OGN
Organon & Co.

1,609
Mkt Cap
$3.49B
Volume
9.98M
52W High
$13.39
52W Low
$5.69
PE Ratio
14.24
OGN Fundamentals
Price
$13.29
Prev Close
$13.25
Open
$13.31
50D MA
$7.82
Beta
0.93
Avg. Volume
17.84M
EPS (Annual)
$0.7171
P/B
4.60
Rev/Employee
$621,600.00
$10,095.68
Loading...
Loading...
News
all
press releases
Organon & Co. (NYSE:OGN) Short Interest Update
Organon & Co. (NYSE:OGN - Get Free Report) saw a large drop in short interest in the month of April. As of April 15th, there was short interest totaling 18,609,663 shares, a drop of 15.9% from the March 31st total of 22,133,518 shares. Based on an average trading volume of 9,901,209 shares, the...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Organon & Co. (NYSE:OGN) Declares $0.02 Quarterly Dividend
Organon & Co. (NYSE:OGN) announced a quarterly dividend on Thursday, April 30th. Investors of record on Monday, May 11th will be paid a dividend of 0.02 per share on Thursday, June 11th. This...
MarketBeat·2d ago
News Placeholder
Organon (OGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·3d ago
News Placeholder
Organon (OGN) Q1 Earnings and Revenues Miss Estimates
Organon (OGN) delivered earnings and revenue surprises of -14.87% and -0.48%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
Organon Reports Results for the First Quarter Ended March 31, 2026
Organon (NYSE: OGN) today announced its results for the first quarter ended March 31, 2026. First Quarter 2026 Revenue in $ millions Q1 2026 Q1 2025 VPY VPY ex-FX Womens Health $ 389 $ 463 (16...
Business Wire·3d ago
News Placeholder
Organon Stock's Momentum Score Jumps As $11.75 Billion Sun Pharma Takeover Deal Sparks Global Pharma Consolidation Push
Organon momentum score jumps as Sun Pharma's $11.75B all-cash acquisition deal boosts outlook, lifting stock trends across timeframes.read more...
Benzinga·3d ago
News Placeholder
Organon & Co. (NYSE:OGN) Given "Neutral" Rating at BNP Paribas Exane
BNP Paribas Exane reaffirmed a "neutral" rating and set a $14.00 price target (up from $12.00) on shares of Organon & Co. in a research note on Wednesday...
MarketBeat·3d ago
News Placeholder
Henlius And Organon Get EU Green Light For First Pertuzumab Biosimilar
(RTTNews) - Shanghai Henlius Biotech Inc. (2696.HK) and Organon & Co. (OGN) on Wednesday, have announced that the European Commission has given the thumbs up for POHERDY, the first and only pertuzumab biosimilar approved in Europe...
Nasdaq News: Markets·3d ago
News Placeholder
Organon Cancels First Quarter Earnings Call
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has canceled its first quarter 2026...
Business Wire·4d ago
News Placeholder
Organon & Co. (NYSE:OGN) Rating Lowered to Hold at BNP Paribas Exane
BNP Paribas Exane lowered shares of Organon & Co. from a "strong-buy" rating to a "hold" rating in a research note on Tuesday...
MarketBeat·4d ago
<
1
2
...
>

Latest OGN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.